Intensive Care Medicine Experimental (ICMx) is a peer-reviewed open access journal published under the SpringerOpen brand.
The idea of extracorporeal blood purification (aside from classical renal replacement therapy) to eliminate injurious mediators of the sepsis syndrome has received increasing interest over the last years. In fact, blood purification techniques, such as hemoadsorption, are already widely used in clinical practice due to its plausible theoretical rationale, despite lack of clear evidence. Moreover, some recent studies have raised important risk-benefit concerns underlining the fundamental need of further research in this field.
This thematic collection invites authors to focus on both pre-clinical and clinical approaches to explore future perspectives of blood purification in the additive treatment of sepsis. The aim is not only to contribute to an improved understanding of the molecular mechanisms influenced by blood purification but also to set the stage for taking the next steps to improve the clinical management.
Submit your manuscript to this collection through the participating journal.
-
Klaus Stahl, MD
Klaus Stahl is a nephrologist,gastroenterologist and intensivist at Hannover Medical School in Germany. He is interested in clinical and translational research in septic shock,ARDS and liver failure. A special focus of his research lies on extracorporeal treatment modalities such as therapeutic plasma exchange in septic shock and ECMO in ARDS. As PI of the EXCHANGE study program,he has explored use of therapeutic plasma exchange in refractory septic shock in both clinical trials as well as translational experiments. As a co-founder of the BonHanZA study group he is excited to tackle a broad range of novel questions in critical care medicine.
Showing 1-11 of 11 articles
